MNKD-201, an inhaled formulation of nintedanib for IPF, was shown to be safe and well tolerated in a clinical trial with ...

Shionogi and InterMune have announced the marketing approval of pirfenidone (Pirespa) for the treatment of idiopathic pulmonary fibrosis (IPF ... There are presently no drugs approved specifically ...

Aileron Therapeutics' Phase 1b trial shows LTI-03 improved biomarkers and reduced SPD levels, indicating the potential to ...

Patients in the US with serious lung disease idiopathic pulmonary fibrosis (IPF) have gone from no approved drugs to two after the FDA cleared products from Roche and Boehringer Ingelheim. The ...

Boehringer Ingelheim is seeking regulatory approval for nerandomilast after a Phase III trial in idiopathic pulmonary ...

Endeavor BioMedicines has completed a third round financing, raising an impressive $132.5 million to fund trials of its two clinical-stage drug candidates for pulmonary fibrosis and solid tumours.

BAL findings showed infectious lung disease in 123 patients and noninfectious lung disease in 198 patients, with drug-induced ILD in ... such as severe pulmonary infection, severe heart disease ...

Identifying the underlying causes of prolonged lung inflammation associated with radiographic abnormalities could be key understanding long COVID and other lung conditions, researchers say.

London-based GSK is crossing the pond to form a new lung disease research collaboration with Boston scientists. The Big Pharma is joining forces with researchers from the Center for Regenerative ...

On Wednesday, Aileron Therapeutics Inc (NASDAQ; ALRN) revealed topline data from Cohort 2 of its Phase 1b trial of safety and tolerability of inhaled LTI-03 for idiopathic pulmonary fibrosis (IPF).